Albinterferon α-2b: a genetic fusion protein for the treatment of chronic hepatitis C
- 7 December 2007
- journal article
- research article
- Published by Springer Nature in Nature Biotechnology
- Vol. 25 (12) , 1411-1419
Abstract
Nature Biotechnology journal featuring biotechnology articles and science research papers of commercial interest in pharmaceutical, medical, and environmental sciences.Keywords
This publication has 68 references indexed in Scilit:
- Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis CHepatology, 2007
- Mechanism of apoptosis induced by IFN-α in human myeloma cells: Role of Jak1 and Bim and potentiation by rapamycinCellular Signalling, 2007
- Diagnosis and treatment of chronic hepatitis C infectionBMJ, 2006
- A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patientsJournal of Hepatology, 2006
- Pharmacokinetic Consequences of PegylationDrug Delivery, 2006
- Global epidemiology of hepatitis C virus infectionThe Lancet Infectious Diseases, 2005
- Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirinJournal of Hepatology, 2005
- Preparation and characterization of poly(D,L-lactide-co-glycolide) microspheres for controlled release of human growth hormoneAAPS PharmSciTech, 2003
- Peginterferon ??-2a (40kD) [Pegasys??] Improves HR-QOL Outcomes Compared with Unmodified Interferon ??-2a [Roferon??-A]PharmacoEconomics, 2003
- Melanoma Peptide MART-1(27−35) Analogues with Enhanced Binding Capacity to the Human Class I Histocompatibility Molecule HLA-A2 by Introduction of a β-Amino Acid Residue: Implications for Recognition by Tumor-Infiltrating LymphocytesJournal of Medicinal Chemistry, 2000